This document discusses how an estimated 2.4 million people in the U.S. are living with hepatitis C infection, while up to 1.59 million people could be living with hepatitis B in the U.S. The need for expanded, standardized, and reliable viral hepatitis surveillance continues to impact public health efforts, resources, and response across the U.S. to this epidemic.
The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV.
The Viral Hepatitis National Progress Report provides information on progress in the implementation of recommended interventions and the impact these interventions are having on prevention of viral hepatitis transmission, disease, and associated mortality.
The resources presented here are based on data obtained from the Hepatitis B Foundation patient engagement survey in 2020. The survey was an anonymous and online and was offered globally for individuals living with chronic hepatitis B (CHB) and aged 18 years old and older. It received 1,707 responses from people living in 100 countries around the globe.
In 2019, NASTAD launched HepTAC, an online technical assistance (TA) and capacity building center for health department hepatitis programs. The primary goal of HepTAC is to build state and local technical expertise and enhance health department capacity to eliminate viral hepatitis. Direct technical assistance is provided primarily via the online platform using video conference technology to connect NASTAD Hepatitis team staff and its consultants to health department hepatitis staff across the county.
In recognition of Hepatitis Awareness Month, NACCHO is launching a new infographic characterizing viral hepatitis trends in the U.S., opportunities and barriers related to the prevention and elimination of viral hepatitis, and the role of local health departments (LHDs) in hepatitis prevention and elimination.
People experience harm in different, complex ways at both the structural and interpersonal levels. When people are criminalized because of illicit drug use, criminalized labor (like drug selling or sex work), or other stigmatized actions that are often survival behaviors, they are also more vulnerable to experiencing interpersonal violence.
As the United States heads into its third year in the fight against COVID-19, Americans have seen firsthand the importance of a robust and comprehensive response to public health emergencies and epidemics. The same is true for chronic viral hepatitis, a condition that impacts an estimated 3.3 million Americans. Without comprehensive plans to eliminate viral hepatitis, the US will fall short of reaching the World Health Organization’s (WHO’s) goal of fully eliminating the virus by 2030.
Hear from pharmacists across the country who are providing viral hepatitis care in unique settings. The webinar discusses opportunities and barriers to increasing pharmacist involvement in viral hepatitis care.
The National Harm Reduction Technical Assistance Center (NHRTAC) Training Deck on Harm Reduction and Syringe Access is a customizable PowerPoint slide deck training designed to provide an overview on the foundations of harm reduction philosophy and practice, drug user health issues and trends, and increase cultural competence and humility when working with people who use drugs.
